Tissue Plasminogen Activator for Acute Ischemic Stroke

1995/12/14 by The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group · 16 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Acute Ischemic Stroke Management #Acute stroke #Blood Coagulation and Thrombosis Mechanisms #Brain ischemia #Cardiology #Clinical trial #Fibrinolytic agent #Internal medicine #Intracerebral hemorrhage #Ischemia #Ischemic stroke #Medicine #Modified Rankin Scale #Protease and Inhibitor Mechanisms #Randomized controlled trial #Recombinant tissue plasminogen activator #Stroke (engine) #Subarachnoid hemorrhage #Surgery #T-plasminogen activator #Tissue plasminogen activator

paper · doi:10.1056/nejm199512143332401

openalex publication_date 1995/12/14 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/05

Abstract

Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of intracerebral hemorrhage in early clinical trials. We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial when treatment was begun within three hours of the onset of stroke.

Citations

• A Multiple Testing Procedure for Clinical Trials

Cited by

• From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue
• 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
• Stroke
• Cincinnati Prehospital Stroke Scale: Reproducibility and Validity
• Ischemic Posterior Circulation Stroke: A Review of Anatomy, Clinical Presentations, Diagnosis, and Current Management
• Comparison of MRI and CT for Detection of Acute Intracerebral Hemorrhage
• Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
• Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator
• Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke
• Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
• Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials
• Mortality of stroke patients treated with thrombolysis: Analysis of nationwide inpatient sample
• Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke
• Hemorrhagic transformation in acute ischemic stroke: hemorrhagic subtypes and symptomatic intracranial hemorrhage
• Stroke: Epidemiology, Risk Factors, Signaling Pathways, and Clinical Management
• Stroke [wikipedia]